Evommune, Inc. (EVMN)
NYSE: EVMN · Real-Time Price · USD
12.82
-0.47 (-3.54%)
At close: Jul 1, 2026, 4:00 PM EDT
12.83
+0.01 (0.08%)
Pre-market: Jul 2, 2026, 8:36 AM EDT
Evommune Revenue
Evommune had revenue of $10.00M in the twelve months ending March 31, 2026, up 233.33% year-over-year. In the year 2025, Evommune had annual revenue of $13.00M with 85.71% growth.
Revenue (ttm)
$10.00M
Revenue Growth
+233.33%
P/S Ratio
46.18
Revenue / Employee
$208,333
Employees
48
Market Cap
461.76M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 13.00M | 6.00M | 85.71% |
| Dec 31, 2024 | 7.00M | 2.00M | 40.00% |
| Dec 31, 2023 | 5.00M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionEVMN News
- 1 day ago - Septerna price target lowered to $45 from $52 at Guggenheim - TheFly
- 2 days ago - Evommune price target lowered to $26 from $55 at Morgan Stanley - TheFly
- 2 days ago - Evommune downgraded to Neutral from Buy at H.C. Wainwright - TheFly
- 2 days ago - Evommune price target lowered to $28 from $53 at Clear Street - TheFly
- 2 days ago - Evommune downgraded to Market Perform from Outperform at William Blair - TheFly
- 3 days ago - Evommune announces Phase 2b trial of EVO756 did not meet primary endpoint - TheFly
- 3 days ago - Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria - Business Wire
- 9 days ago - Apogee deal gives positive readthrough to Evommune pipeline, says Clear Street - TheFly